10/594926

## IAP2 Rec'd PCT/PTO 29 SEP 2006

PTO/SB/08a (08-03)
Approved for use through 07/31/2006. OMB 0651-0031

U.S.Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. National Phase of PCT/ IL2005/000358 Substitute for form 1449A/PTO Application Number Filing Date INFORMATION DISCLOSURE Francesca LEVI-SCHAFFER et al First Named Inventor STATEMENT BY APPLICANT Not Yet Available Art Unit (use as many sheets as necessary) Examiner Name Not Yet Available Attorney Docket Number 32379 of Sheet U.S. PATENT DOCUMENTS Pages, Columns, Lines, Where Name of Patentee or Relevant Passages or Relevant Publication Date Document Number Applicant of Cited Document Cite No. 1 Examiner MM-DD-YYYY Figures Appear Number-Kind Code<sup>2 (Flame)</sup>

			TO THE POOL	IMPNITS		_
Examiner Initials*	Cite No. 1	Foreign Patent Documents	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
***************************************	2	Country Code <sup>b</sup> Number <sup>c</sup> Kind Code <sup>b</sup> ((f known) PCT WO 03/03/03035 PCT WO 03/04/02	04-17-2003 	Digler et al. Thomas et al.		
Examin		/Nora Rooney/		Date Considered	09/29/20	10

"EXAMINER, Initial if reference considered, whether or not citation is in conformance with MPEP 698. Draw line through citation if not in conformance and not considered, include copy of copy of this form with next communication to applicant." Applicants winque calsion designation number (opional). "See Kinds Codes considered, Include copy of copy of this form with next communication to be specified to the document. In citation of the year of the refine of the Engineer must precede the senial number of the patent document. "And of document under VMPO Standard ST. 16 if possible." Applicant is to place a check mark here if English language

Transition is attached.
This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or fetain a benefit by the public which is to file (and by the This collection of information is required by 35 U.S.C. 122 and 37 CFR 1.14, this collection is estimated to take 2 hours to complete, including the properties of the properties o

10/594926

## IAP2 Rec'd PCT/PTQ 293SEP 2006

Approved for use through 06/30/2006. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

				to a collection of information unless it contains a valid OMB control number.  Complete if Known					
Inder the Paperwoo	rk Reduction A	ct of 1995, no persons a	re required to respond	16 a consection of mice maner	Complete if Known				
	Suhe	titute for form 1449A/F	то	Application Number National Phase of PC 1/ 1L 2003		05/000358			
				Filing Date Herewith  Figure Named Inventor Francesca LEVI-SCHAFFER					
INFO	RMAT	ION DISCL	OSURE	First Named Inventor	et al				
COT A 7	CEMEN	T BY APPL	ICANT	Group Art Unit	Not Yet Available				
SIAI	FIAIF	IDIAIL		Examiner Name	Not Yet Available '				
(,	ee as mar	ry sheets as neces	sary)						
				Attorney Docket Number	32379				
Sheet	2			NON PATENT LITERATU	JRE DOCUMENTS				
		OTHER	he author (in CAP)	ITAL LETTERS), title of the article	(when appropriate), title of the	T <sup>2</sup>			
Examiner	Cite								
Initials	itidis No. item (book, magazine, journai, schal symposium, schal symposium								
	3	Ott et al. "Activ	ating and Inhib	bitory Signaling in Mast Cer	is: New Opportunities				
		Therapeutic int	ervention?", Jo	ontory Signating in Mast Cer- rurnal of Affergy and Chinica	minunology, 100. 129				
	1	440, 2000.			L. L. Thoir Molecular				
	4		'Human Natura	al Killer Cell Receptors: Insi	gnts into Their Wolcetian				
		runction and 3	tructure , Jour	nar of Centural and Morecula	r Medicine, 7(4), 570-567,				
		2003.			CID CO A Mamber of				
	5	Cantoni et al. "	Molecular and	Functional Characterization	of IRp60, A Member of				
		me minimunogio	bulin Superfar	mity That Functions as An in	difference in 1999				
	1								
	6	the minimung obtains supertaininy was transcribed by 1995. Human NK Cells", European Journal of Immunology, 29: 5148-3159, 1999.  Human NK Cells", European Journal of Immunology, 19: 5148-3159, 1999.  Bachelet et al. "The inhibitory Receptor IRPGO (CD300a) 18 Expressed and European Journal of Immunology, 175: 7989-7995, Functional an Human Mast Cells". The Journal of Immunology, 175: 7989-7995.							
	10	Functional on	Human Mast C	ells". The Journal of Immur	iology, 1/3: /989-7993,				
		2005			1 700 4 -611				
	17-	Munitz et al "	The inhibitory	Receptor IRp60 (CD300a) S	Suppresses the Effects of IL-				
	1'	2005. Munitz et al. "The inhibitory Receptor IRp60 (CD300a) Suppresses the Effects of IL- Munitz et al. "The inhibitory Receptor IRp60 (CD300a) Suppresses the Effects of IL- 5, 6M-69f and Education on Human Peripheral Blood Sesinephile", Blood, 1st Ed.							
***************************************		Paper Prepub	lished Online,	P.1-40, 2005.	21 5 1 -41-	+			
	- 8								
***************************************		End of the Be	ginning?". Lec	ture Abstracts, 2005.					
	9	End of the Beginning?", Lecture Abstracts, 2005.  Bachelet et al. "IRp60 Modulates An array of Human Mast Cell Functions", Journal							
		l et Allerey an	Clinical Imm	unology, S206, 2005. Abstra	act.				
		of Affergy and	a Chinesia						
						+			
						+			
		+				+			
	$\rightarrow$					+			
						T			
					Considered				
C: atur					Considered				

EXAMINER, Initial if reference considered, whether or not citation is in conformance with NPEP 609. Draw line through citation if not in conformance and not

"EXAMPLES, initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not conformate include copy of this form with next communication to applicant.

Applicant for supervised includes copy of this form with next communication to applicant.

This collection of information is required by 37 CFR 1.97 and 1.98. The 1.09 capes a check must keep if English language Translation is attached.

SUBSTRO process an application Confidentially is governed and in required to both or retain a benefit by the public which is till like of the Language and perfect of the complete including application. Confidentially is governed or the substrate of the complete including application. The confidentially is governed from the USFP. The well vary depending upon the individual case. Any period and translation of the complete including the substrate that the confidence of the complete including the substrate that the complete including the substrate the complete including the substrate that the complete including the complete including the substrate that the complete including the substrate that the confidence of the complete including the substrate that the complete including the substrate that the confidence of the complete including the substrate that the complete including the substrate that

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

/Nora Rooney/

09/29/2010